Latest news with #SeriesE
Yahoo
2 days ago
- Business
- Yahoo
Omada Health targets valuation of over $1 billion in US IPO
(Reuters) -Virtual chronic care provider Omada Health is targeting a valuation of about $1.1 billion in its initial public offering in the United States, signaling a comeback for capital markets after several months of slowdown in listings. The company said on Thursday it would sell 7.9 million shares in a range of $18 to $20 per share, potentially fetching up to $158 million if priced at the upper limit. While U.S. President Donald Trump's tariff whiplash has roiled markets and cast a shadow on new listings, companies in sectors perceived as less sensitive to economic headwinds are pushing ahead with their initial public offerings. The San Francisco, California-based company, last raised $192 million in a Series E funding round in 2022. Omada has applied to list its common stock on the Nasdaq under the symbol "OMDA". Goldman Sachs, Morgan Stanley and Barclays are among the underwriters for Omada's offering.
Yahoo
2 days ago
- Business
- Yahoo
Omada Health targets valuation of over $1 billion in US IPO
(Reuters) -Virtual chronic care provider Omada Health is targeting a valuation of about $1.1 billion in its initial public offering in the United States, signaling a comeback for capital markets after several months of slowdown in listings. The company said on Thursday it would sell 7.9 million shares in a range of $18 to $20 per share, potentially fetching up to $158 million if priced at the upper limit. While U.S. President Donald Trump's tariff whiplash has roiled markets and cast a shadow on new listings, companies in sectors perceived as less sensitive to economic headwinds are pushing ahead with their initial public offerings. The San Francisco, California-based company, last raised $192 million in a Series E funding round in 2022. Omada has applied to list its common stock on the Nasdaq under the symbol "OMDA". Goldman Sachs, Morgan Stanley and Barclays are among the underwriters for Omada's offering. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
4 days ago
- Business
- Mint
Whatfix expects AI products to contribute 20% of revenue as it gears up for IPO
Whatfix, a business-to-business (B2B) software-as-a-service (SaaS) startup, expects its artificial intelligence (AI) products' contribution to revenue to grow at least 13 times, up from its current contribution of 1.5%, within the next 18 months, according to the company's co-founder. 'By the end of calendar year 2026, I expect that AI products will contribute at least 15% to 20% to revenue," Whatfix co-founder and chief executive officer Khadim Batti told Mint in an interview. The company's core business is improving digital adoption of enterprise software through nudges, i.e., tooltips on different parts of a workflow. The intention is to make it easier and more comfortable for users to 'adopt' such software, thereby improving productivity and efficiency. The company has increasingly been focusing on AI as it looks to become profitable within the next two years, the same timeline it has set for itself to make an initial public offering (IPO). 'Currently, we're at -27% Ebitda in 2025. In 2026, alongside growth, we will be at -5% or -6%," Batti said. Also read | Whatfix secures funding from Warburg Pincus, SoftBank at $900 million valuation; eyes IPO in two years But Whatfix's tryst with AI isn't new. In fact, it goes as far back as 2019, when it acquired Airim, a startup that provides AI-powered personalisation for users and customers. 'Combined with Airim's AI-powered personalised engine, Whatfix users can now expect hyper-personalised in-app guidance at their point of need," the company had said in a statement back then. Whatfix last raised funds in September in a $125 million Series E round led by private equity firm Warburg Pincus, with SoftBank Vision Fund 2 also participating. The fresh funds bumped the company's valuation to $900 million. Backers of the company include Dragoneer, Peak XV Partners, Eight Roads and Cisco Investments. Over the past nine months, several startups and companies have been pivoting their AI offerings to become agentic in nature. This technology has emerged as easily monetizable and promises to boost productivity, especially in the enterprise. As a result, investors, too, have been piling on, Mint previously reported. Betting on agents The only thing that's missing with the agentic push across industries is adoption. For context, adoption of agentic AI systems stood at 1% in 2024, according to research firm Gartner. That number is supposed to shoot up to 33% by 2028. The most common complaint from the enterprise has been return on investment. Batti believes that its core product, digital adoption platform (DAP), which accounts for 93% of Whatfix's revenue, will be the game-changer. 'One of the reasons that organizations complain about return on investment on agentic AI systems is because people are not utilising it on a regular basis. Agents are sitting somewhere in the system, and users are trained on one or two use cases. But they don't know that agents can do several other things." Also read | You've heard of LLMs. Prosus is building its own LCM for commercial smarts. The remaining 7% is accounted for by other product verticals, analytics, and Mirror, an application simulation software builder. 'Now we've started a journey where we want to embed AI into each product in our portfolio," he added. Whatfix is working on its own AI agent that can be integrated with existing enterprise software. Agentic AI companies usually develop agents for specific use cases or create a marketplace of agents suited to different tasks. Instead, Whatfix has chosen to use a one-size-fits-all agent that can, in Batti's words, 'perform a task on any software. If our agent is not the default, and something else is, it'll work with those." The rollout for this is planned over the next two to three months. AI focus As part of Whatfix's doubling down on AI, the company created a separate go-to-market division, whose sole job is to find different use cases and find a market for them. Currently, the team has pulled up two use cases, both of which have early adopters already. The first one is an assistant for task automation, while the other is for administrators to 'simplify their job and make them more productive," according to Batti. From September this year, Whatfix plans to have one up and running in beta. By November, it plans to be monetized. But as the company shifts to becoming AI-first, it's but a given that compute costs will rise. But Batti disagrees, saying that with their implementations, there isn't an expectation that people are constantly engaging their platform, but more realistically, between 3-5% of the time. 'I haven't seen a negative hit in terms of our gross margins." As part of its AI push, Whatfix created ScreenSense, a proactive AI-based technology that fits on top of its existing verticals. It crunches several clicks or parts of a workflow into fewer steps, therefore making users more productive. Earlier, Whatfix's DAP would simply guide users from one end of a workflow to another in a step-by-step manner to ensure that users became familiar with using an enterprise application. Simply put, it was reactive. Also read | Cashfree Payments eyes profitability as it focuses on $250-300 million monthly in cross-border payments For example, when a user begins creating a purchase order, ScreenSense is able to detect the intention behind it. Instead of having a user go through the entire workflow to create the order, the technology simply automates the entire process, reducing clicks and time taken. 'In the next 6-12 months, we want to continue to enhance ScreenSense so that it can not only work with our products but also can start working with AI agents or co-pilots, which are built by third parties," said Batti. The hope is that with this, it will not only increase digital adoption of new technologies being introduced by Whatfix's clients into their ecosystems but also boost user productivity. No product left behind Even as Whatfix reworks its own ecosystem to become more AI-heavy, the company says its core offerings won't be phased out but will evolve alongside the new innovation it is planning. On some level, the rationale makes sense. Companies don't change their software stacks overnight. Solutions for customer relationship management and enterprise resource planning are often deployed on such a large scale that overhauling them overnight could be challenging, if not outright disastrous. 'We will definitely continue to increase our investment to become AI-first. But our existing product lines, I would say it will continue in your future. It's not going to discontinue. We are continuing to invest there as well," Batti said. But even with those investments, Whatfix's core products may be running on borrowed time. 'Our core products will fundamentally shift. But it'll take at least five to seven years. That's the mid-term view." For example, with their analytics vertical, instead of generating dashboards for their clients' users, Whatfix now uses natural language processing. Users can opt to simply input what they're looking for, and Whatfix generates it for them.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Groww parent Billionbrains files confidential IPO papers with Sebi
Billionbrains Garage Ventures, the parent company of Groww, has confidentially filed a draft red herring prospectus (DRHP) for an initial public offering (IPO) with the Securities and Exchange Board of India (Sebi). The Bengaluru-based company disclosed the filing through a newspaper advertisement on Monday. The IPO size is estimated at ₹8,000 crore and will include both primary and secondary shares. This will make it the largest-ever offering by a capital market firm in India. In November last year, Groww re-domiciled from the United States to India to pursue a listing on domestic stock exchanges. The stock broker is backed by investors such as Tiger Global, Peak XV Partners and Ribbit Capital. Earlier this month, Singapore's sovereign wealth fund GIC sought approval from the Competition Commission of India (CCI) to acquire a 2.14 per cent stake in the company. This is part of the pre-IPO funding round, which could take the company's valuation to around $6.5 billion — double its 2021 valuation of $3 billion during its Series E fundraise. For the financial year ended March 2024, the company reported revenue of ₹3,145 crore and a net loss of ₹805 crore, driven in part by a one-time tax expense related to the relocation. Groww surpassed Zerodha last year to become the largest stock broker in terms of number of clients. As of March 2025, Groww's active clients rose 36 per cent to nearly 13 million, boosting its market share by 286 basis points to 26.3 per cent. Zerodha's market share in FY25 fell by 184 basis points to 16 per cent. However, Zerodha remains the most profitable stock broker. Groww also joins a slew of firms opting for the confidential filing route for IPOs. These include Physics Wallah, Tata Capital and Imagine Marketing (Boat).
Business Insider
22-05-2025
- Business
- Business Insider
Hinge Health just broke open the digital health IPO market. Here's who's getting rich.
Physical therapy startup Hinge Health finally went public Thursday in a watershed moment for the digital health market. Hinge Health's stock price popped after debuting on the New York Stock Exchange, soaring to $39.25 per share, 23% above its initial public offering price of $32 a share. The $32 IPO share price valued Hinge Health at about $2.6 billion, based on shares outstanding after the IPO. At the market close, however, the company was worth about $3 billion. It's a strong start for Hinge Health's public market debut, and the first true glimmer of hope for the digital health IPO market in years. The last wave of healthcare public market exits, in 2021, saw 23 healthcare companies go public via IPO or SPAC. In the following three years, only four healthcare companies went public. Only two of those, Waystar and Tempus AI, are still trading on the stock market. Hinge Health, founded in 2014 to provide virtual care for musculoskeletal conditions, was forced to consider a delay for its IPO plans in early April after President Donald Trump announced sweeping tariffs on imported goods from other countries, causing a sharp drop in the stock market. It resumed those efforts publicly this month as the market stabilized. Hinge Health raised $437 million in the IPO, which included $273 million in proceeds to the company and $164 million to its selling shareholders. Hinge Health's $2.6 billion IPO valuation is a 52% markdown from its last private valuation of $6.2 billion. It notched that valuation in a 2021 $400 million Series E round co-led by Tiger Global and Coatue Management. We don't know what Hinge Health's investors paid for their shares, so we can't calculate their profit. However, since Hinge Health's shares opened on the stock market at $39.25, we used that price to determine the worth of their stakes. Here's what the stakes of all of Hinge Health's major investors and executives are worth after the IPO. Insight Partners, an investor: $433 million Venture capital and private equity firm Insight Partners owns the largest stake in Hinge Health with about 12.3 million shares, or 13.7% of the company. The firm led Hinge Health's $26 million Series B fundraise in 2018. Teddie Wardi, a managing director at Insight Partners, has served on Hinge Health's board of directors since the firm's investment. Insight Partners later participated in Hinge Health's Series C and D rounds in 2020 and 2021, respectively. Insight Partners sold 1.25 million shares in Hinge Health's IPO, which at the $32 IPO price would have brought in $40 million. At the $39.25 market debut price, the firm's remaining stake is worth about $433 million. Daniel Perez, cofounder and CEO: $414 million Daniel Perez's first encounter with physical therapy came after a bike crash when he was 13 years old, which forced him to undergo three surgeries and 12 months of rehabilitation. He started Hinge Health alongside executive chairman Gabriel Mecklenburg to improve the accessibility of musculoskeletal care and reduce the specialty's reliance on surgeries and opioids. Hinge Health is Perez and Mecklenburg's third venture, after the Oxbridge Biotech Roundtable, which aimed to bridge the gap between life sciences academia and markets, and Marblar, a platform designed to generate commercial uses for scientific discoveries. Perez is Hinge Health's largest individual shareholder. He owns about 10.6 million shares, or 13.1% of the company. He didn't sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $414 million. Atomico, an investor: $309 million Atomico is a London-based venture firm started in 2006 by Skype cofounder Niklas Zennström. The firm led Hinge Health's $8 million Series A in 2017, when the startup was based in London. (Hinge Health moved its headquarters to San Francisco the same year.) Atomico later participated in Hinge Health's Series B, C, and D funding rounds. Atomico owns about 7.9 million shares, or 9.8% of the company. The firm sold 1,497,546 shares in the IPO, which at the IPO price of $32 would have brought in about $48 million. At the $39.25 market debut price, the firm's remaining stake is worth about $309 million. Tiger Global, an investor: $207 million Investment firm Tiger Global first backed Hinge Health in 2021, co-leading its $300 million Series D alongside Coatue Management. In October of that year, Tiger Global also co-led the company's $400 million Series E, also alongside Coatue. The $400 million Series E round boosted Hinge Health to the $6.2 billion valuation that Hinge Health was forced to slash in its IPO. Tiger Global has drawn criticism in recent years for backing startups at extraordinarily high valuations, particularly during 2021's venture investment peak. Tiger Global owns about 5.3 million shares, or 6.5% of the company. The firm sold 258,183 shares in the IPO, which at the IPO price of $32 would have brought in about $8.3 million. At the $39.25 market debut price, the firm's remaining stake is worth about $207 million. Coatue Management, an investor: $185 million New York-based Coatue Management invests across all private and public fundraising stages, with venture capital, private equity, and hedge fund management units. The firm co-led Hinge Health's $300 million Series D alongside Tiger Global in January 2021, then co-led its $400 million Series E with Tiger Global that October. Hinge Health's S-1 filing notes that Coatue will sell $50 million in Series E preferred shares back to the company immediately before Hinge's IPO. That agreement was created in February, per the filing. The company didn't share a reason for the stock repurchase. Coatue owns about 4.7 million shares of common stock, or 5.8% of the company. The firm didn't sell any shares in the IPO. At the $39.25 market debut price, the firm's stake is worth about $185 million. 11.2 Capital, an investor: $169 million San Francisco-based 11.2 Capital backs early-stage tech startups and wrote one of the first checks into Hinge Health. The firm led Hinge Health's seed round in 2016, and invested further in its Series A, B, C, and D rounds, according to the firm. 11.2 Capital owns about 4.3 million shares, or 5.4% of Hinge Health. The firm sold 788,691 shares in the IPO, which at the IPO price of $32 would have brought in about $25 million. At the $39.25 market debut price, the firm's remaining stake is worth about $169 million. Bessemer Venture Partners, an investor: $161 million Bessemer Venture Partners backs early-stage and growth-stage startups through venture and private equity investments. The firm has more than 300 companies in its portfolio, according to its website. Bessemer led Hinge Health's $90 million Series C in February 2020. Bessemer partner Elliott Robinson has served on Hinge Health's board of directors since that round. The firm also participated in Hinge Health's $300 million Series D round in January 2021. Bessemer Venture Partners owns about 4.1 million shares, or 5.1% of the company. The firm sold 725,066 shares in the IPO, which at the IPO price of $32 would have brought in about $24 million. At the $39.25 market debut price, its remaining stake is worth about $161 million. Gabriel Mecklenburg, cofounder and executive chairman: $158 million Gabriel Mecklenburg cofounded Hinge Health alongside Perez, personally inspired by the months of physical therapy he completed after tearing his ACL in a judo sparring session. Mecklenburg served as the company's COO for six years. It was a familiar role for him; he'd held the COO title at the two companies he started with Perez before Hinge Health, Oxbridge Biotech Roundtable and Marblar. In 2021, he transitioned to his current role of executive chairman. In addition to his work with Hinge Health, he's served on the board of addiction care startup Pelago since 2022. Mecklenburg owns about 4 million shares, or 4.9% of the company. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $158 million. IP2IPO, an investor: $42 million IP2IPO, named IP2IPO Portfolio LP in Hinge Health's S-1, specializes in moving innovative technologies, talent, and intellectual property from academic institutions to commercial industries. Both Perez and Mecklenburg stepped away from pursuing higher education degrees to build Hinge Health. Perez was taking a leave of absence from a Ph.D. program in biochemistry at the University of Oxford, while Mecklenburg was researching musculoskeletal regenerative medicine at Imperial College London. IP2IPO is a subsidiary of IP Group, a London-based firm that backs breakthrough science and tech companies. IP Group says it's the founding investor in Hinge Health. The firm told BI it actually invested in Marblar, Perez and Mecklenburg's previous startup, back in 2012. That investment rolled over into Hinge Health. "As the UK's leading investor in university spinouts, we met Dan whilst he was in Oxford, working on brilliant ideas and showing real entrepreneurial spirit and tenacity," said Robert Trezona, a partner at IP Group. He said IP Group invested around £1 million, or about $1.12 million at the time, shortly after meeting Perez. IP2IPO owns about 1.1 million shares, or 1.3% of the company. The firm sold about 47,000 shares in the IPO, which at the IPO price of $32 would have brought in about $1.5 million. At the $39.25 market debut price, its remaining stake would be worth about $42 million. Heuristic Capital, an investor: $40 million Early-stage VC firm Heuristic Capital was founded in 2016, and first invested in Hinge Health's seed round that same year. The Santa Clara, California-based firm then invested in Hinge Health's four subsequent raises, from Hinge Health's Series A to its Series D. Heuristic Capital told BI that the Hinge Health team worked out of the firm's San Francisco office in the startup's early days, moving into an independent office in the Bay Area after successfully closing a Series A round. The firm owns about 1 million shares of Hinge Health, or 1.3% of the company. It sold 194,305 shares in the IPO, which at the initial share price of $32 would have brought in about $6.2 million. At the $39.25 market debut price, its remaining stake would be worth about $40 million. Jim Pursley, president: $24 million Longtime digital health executive Jim Pursley joined Hinge Health as its president in 2021. He'd previously worked with the Hinge Health team as an advisor from 2017 to 2019. Pursley came to Hinge Health from Livongo, where he spent six years as the diabetes company's chief commercial officer through its 2019 IPO. He left the company shortly after Livongo announced its $18.5 billion acquisition by Teladoc in 2020. He also held leadership roles at GE Healthcare and Care Innovations, a joint venture between Intel and GE. In addition to his role at Hinge Health, he serves as an independent board member at digital therapeutics company Bodyport. Pursley owns about 604,665 shares. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $24 million. The Vertical Group, an investor: $22 million The Vertical Group, named in Hinge Health's S-1 as Vertical GP-8, is a Basking Ridge, New Jersey-based firm that invests in healthcare and biotech companies. Vertical invested in Hinge Health's seed and Series A funding rounds, according to the firm. The firm told BI that it previously sold a portion of its Hinge Health shares in a secondary transaction in 2021, at $77 a share, and another portion in a 2023 secondary sale, at $36 a share. Vertical is also an investor in diabetes care startup Omada Health, according to the firm's website. Omada is the only other digital health company to file to go public so far this year. Vertical GP-8 owns 554,919 shares. The firm sold about 106,000 shares in the IPO, which at the IPO price of $32 would have brought in about $3.4 million. At the $39.25 market debut price, the firm's remaining stake is worth about $22 million. Jon Reynolds, an angel investor: $14 million Jon Reynolds is the cofounder and former CEO of SwiftKey, the AI-powered keyboard app acquired by Microsoft in 2016. He told BI he first backed Hinge Health that same year, participating in the startup's seed and seed extension funding rounds. Reynolds owned about 360,175 shares. He sold 68,605 shares in the IPO, which at the IPO price of $32 would have brought in about $2.2 million. At the $39.25 market debut price, his remaining stake is worth about $14 million. Industry Ventures, an investor: $12 million San Francisco-based Industry Ventures makes VC bets using flexible capital structures, including secondary transactions and buyouts. Hinge Health has never publicly announced a secondary transaction made by Industry Ventures. Hinge Health's S-1 specifies that Industry Ventures invested in the company through its Secondary IX fund, which the firm announced in March 2021. Industry Ventures didn't respond to a request for comment from BI. Industry Ventures owns 307,259 shares. The firm sold 58,526 shares in the IPO, which at the initial share price of $32 would have brought in about $1.9 million. At the $39.25 market debut price, its remaining stake is worth about $12 million. James Budge, CFO: $6.8 million Serial CFO James Budge joined Hinge Health as its finance chief in 2023. According to his LinkedIn, he's been the CFO of at least eight other companies, spanning industries from workforce software to entertainment tech. He's also served on the board of directors of healthtech company Shadowbox since 2022. Budge owns 172,241 shares. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $6.8 million. Kristina Leslie, board member: $343,000 Kristina Leslie joined Hinge Health's board of directors in May 2024 as its audit chair. Leslie, the former CFO of Dreamworks Animation, has spent nearly two decades serving on various company boards, including Glassdoor, CVB Financial Corp., and Rover. According to her LinkedIn, she currently sits on the boards of Sunstone Hotel Investors and Justworks and chairs the board of directors of Blue Shield of California. Leslie owns 8,750 shares. She did not sell any shares in the IPO.
